

## The OncoAlert #ASCO21 Picks

**Track: Kidney Cancer & Bladder Cancer(Drs Toni Choueiri, Neeraj Agarwal, Tian Zhang, Sumanta Pal, Andrea Apolo, Petros Grivas, Axel Merseburger, Daniel Heng, Hans Hammers)**

### LBA5

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma: Randomized, double-blind, phase III KEYNOTE-564 study.

<https://bit.ly/3viN4J7>

### Abstract 4503

The phase 2 trial HCRN GU 16-257 of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in patients with MIBC: impressive cCR rate of 48% and association of high TMB and mutant ERCC2 with outcomes!! [@MattGalsky](#) [@IcahnMountSinai](#)

<https://bit.ly/34d2GBV>

### Abstract 4505

The phase 2 IMMUNOPRESERVE-SOGUG trial of durvalumab plus tremelimumab with RT in pts with localized MIBC showing a CR rate of 81%, and 6-months rates for DFS and OS of 80 and 93%!! <https://bit.ly/3bSd9XH>

### Abstract 4507

Phase 2 study of gemcitabine and cisplatin +/- berzosertib in aUC showing no improvement in PFS with the addition of berzosertib to CG! [@montypal](#) [@cityofhope](#)

Important lesson: never reduce the dose of CG to accommodate an experimental 3rd drug.

<https://bit.ly/3yyxjzH>

### Abstract 4508

First-line pembrolizumab (pembro) in cisplatin-ineligible patients with advanced urothelial cancer (UC): Response and survival results up to five years from the KEYNOTE-052 phase 2 study.

Five yr F/U of Keynote 052 trial of 1st line Pembro in Cis ineligible metastatic

[#bladdercancer](#) Confirmed ORR ~30%, Long median duration of response= 33.4 months

<https://bit.ly/3fKzEyL>

### Abstract 4502

Health-related quality-of-life (HRQoL) analysis from the phase 3 CLEAR trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) for patients (pts) with advanced renal cell carcinoma (aRCC)

<https://bit.ly/2TjKSdb>

